<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">108221</article-id><article-id pub-id-type="doi">10.26442/00403660.2022.04.201460</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Proinflammatory laboratory predictors of pneumonia in ischemic stroke patients: prospective study</article-title><trans-title-group xml:lang="ru"><trans-title>Провоспалительные лабораторные предикторы пневмонии у больных с ишемическим инсультом: проспективное исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3632-291X</contrib-id><name-alternatives><name xml:lang="en"><surname>Kochetov</surname><given-names>Anatoly G.</given-names></name><name xml:lang="ru"><surname>Кочетов</surname><given-names>Анатолий Глебович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., ректор, проф. каф. фармакологии</p></bio><email>ag_kochetov@dpo-ilm.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1023-5490</contrib-id><name-alternatives><name xml:lang="en"><surname>Lyang</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Лянг</surname><given-names>Ольга Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, доц. каф. госпитальной терапии, зав. отд-нием клинической лабораторной диагностики </p></bio><email>ag_kochetov@dpo-ilm.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6621-2052</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhirova</surname><given-names>Irina A.</given-names></name><name xml:lang="ru"><surname>Жирова</surname><given-names>Ирина Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. госпитальной терапии</p></bio><email>ag_kochetov@dpo-ilm.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4684-8440</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivoylov</surname><given-names>Oleg O.</given-names></name><name xml:lang="ru"><surname>Ивойлов</surname><given-names>Олег Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ассистент каф. госпитальной терапии</p></bio><email>ag_kochetov@dpo-ilm.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4228-1694</contrib-id><name-alternatives><name xml:lang="en"><surname>Politidis</surname><given-names>Rita R.</given-names></name><name xml:lang="ru"><surname>Политидис</surname><given-names>Рита Романовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ассистент каф. госпитальной терапии</p></bio><email>ag_kochetov@dpo-ilm.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4295-8172</contrib-id><name-alternatives><name xml:lang="en"><surname>Novozhenova</surname><given-names>Yulia V.</given-names></name><name xml:lang="ru"><surname>Новоженова</surname><given-names>Юлия Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>ассистент каф. госпитальной терапии</p></bio><email>ag_kochetov@dpo-ilm.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Laboratory Medicine</institution></aff><aff><institution xml:lang="ru">АНО ДПО «Институт лабораторной медицины»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">People’s Friendship University of Russia (RUDN University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Federal Center of Brain Research and Neurotechnologies</institution></aff><aff><institution xml:lang="ru">ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-05-26" publication-format="electronic"><day>26</day><month>05</month><year>2022</year></pub-date><volume>94</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>491</fpage><lpage>496</lpage><history><date date-type="received" iso-8601-date="2022-05-25"><day>25</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-05-25"><day>25</day><month>05</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/108221">https://ter-arkhiv.ru/0040-3660/article/view/108221</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. Bacterial pneumonia is a frequent complication of ischemic stroke at the hospital stage. The search for prognostic laboratory markers of pneumonia remains an urgent task, as it will allow to individualize the approach to the treatment and rehabilitation of such patients.</p> <p><bold>Aim</bold>. To investigate the prognostic significance of proteins of the acute phase of inflammation, as well as to evaluate them as early predictors of the development of pneumonia in patients with ischemic stroke.</p> <p><bold>Materials and methods</bold>. The study included 302 patients in the acute period of ischemic stroke. C-reactive protein (CRP), tumor necrosis factor α, interleukin-6 (IL-6), neutrophil elastase, neopterin, serum amyloid A (SAA), secreted phospholipase type 2 (sPLA2) were determined in all patients on the first day by enzyme immunoassay. Statistical data processing was carried out using SPSS and Microsoft Excel software (USA).</p> <p><bold>Results</bold>. At the hospital stage, pneumonia developed in 82/302 patients (27.2%; 95% confidence interval 22.3–32.3%). The levels of CRP, IL-6, sPLA2, SAA and neopterin significantly differed in the presence and absence of pneumonia. Step-by-step logistic regression analysis revealed the significance of IL-6 and CRP concentrations in the prognosis of pneumonia. The threshold value of IL-6 concentration was 3.45 pg/ml (sensitivity – 82.4%, specificity – 66.7%). The prognostic value of a positive result (PPR) in the prognosis of pneumonia was 40%, a negative result (PNR) – 92%. The threshold value of CRP was 1640 mg/l with a sensitivity of 65.8% and a specificity of 74.8%. The PPR of the threshold value of the concentration of CRP was 45%, PNR – 80%.</p> <p><bold>Conclusion</bold>. The measurement of the concentration of IL-6 and CRP on the first day of ischemic stroke makes it possible to identify patients with the greatest risk of pneumonia at the hospital stage. The results of the work indicate the necessity to include CRP and IL-6 in the list of mandatory laboratory tests that should be carried out for each patient with ischemic stroke on the first day from the onset of the disease.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>. Бактериальная пневмония является частым осложнением ишемического инсульта на госпитальном этапе. Поиск прогностических лабораторных маркеров пневмонии остается актуальной задачей, поскольку позволит индивидуализировать подход к лечению и реабилитации пациентов.</p> <p><bold>Цель</bold>. Изучить прогностическую значимость белков острой фазы воспаления и произвести их оценку в качестве ранних предикторов развития пневмонии у пациентов с ишемическим инсультом.</p> <p><bold>Материалы и методы</bold>. В проспективное исследование были включены 302 пациента в остром периоде ишемического инсульта. Всем пациентам в 1-е сутки болезни методом иммуноферментного анализа определяли С-реактивный белок (СРБ), фактор некроза опухоли α, интерлейкин-6 (ИЛ-6), нейтрофильную эластазу, неоптерин, сывороточный амилоид А (SAA), секретируемую фосфолипазу А<sub>2 </sub>(sPLA2). Статистическая обработка данных произведена при помощи программного обеспечения SPSS и Microsoft Excel (США).</p> <p><bold>Результаты</bold>. На госпитальном этапе пневмония развилась у 82 из 302 пациентов (27,2%; 95% доверительный интервал 22,3–32,3%). По наличию и отсутствию пневмонии значимо различались уровни СРБ, ИЛ-6, sPLA2, SAA и неоптерина. Пошаговый логистический регрессионный анализ выявил значимость в прогнозе развития пневмонии концентрации ИЛ-6 и СРБ. Пороговое значение концентрации ИЛ-6 составило 3,45 пг/мл (чувствительность – 82,4%, специфичность – 66,7%). Прогностическая ценность положительного результата (ПЦПР) в прогнозе развития пневмонии составила 40%, отрицательного результата (ПЦОР) – 92%. Пороговое значение СРБ составило 1640 мг/л с чувствительностью 65,8% и специфичностью 74,8%. ПЦПР порогового значения концентрации СРБ была равна 45%, ПЦОР – 80%.</p> <p><bold>Заключение</bold>. Измерение концентрации ИЛ-6 и СРБ в 1-е сутки развития ишемического инсульта позволяет определить пациентов с наибольшим риском развития пневмонии на госпитальном этапе. Результаты работы свидетельствуют о необходимости включения показателей СРБ и ИЛ-6 в перечень обязательных лабораторных исследований, которые должны проводиться каждому пациенту с ишемическим инсультом в 1-е сутки от начала болезни.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ischemic stroke</kwd><kwd>pneumonia</kwd><kwd>biomarker</kwd><kwd>C-reactive protein</kwd><kwd>interleukin-6</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ишемический инсульт</kwd><kwd>пневмония</kwd><kwd>биомаркер</kwd><kwd>С-реактивный белок</kwd><kwd>интерлейкин-6</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Инсульт: Руководство для врачей. Под ред. Л.В. Стаховской, С.В. Котова. М.: МИА, 2014 [Insul't: Rukovodstvo dlya vrachei. Pod red. LV Stakhovskoi, SV Kotova. Moscow: MIA, 2014 (in Russian)].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Кутлубаев М.А. Инфекционно-воспалительные осложнения церебрального инсульта. Клиническая медицина. 2014;10:66-72 [Kutlubaev MA. Infectious-inflammatory complications of cerebral insulitis. Clinical Medicine (Russian Journal). 2014;10:66-72 (in Russian)].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Попова Е.А., Орлов С.В., Позднякова М.А., и др. Профилактика и интенсивная терапия пневмоний у больных с ишемическим инсультом. Сибирский медицинский журнал (Иркутск). 2007;2:41-4 [Popova EA, Orlov SV, Pozdnjakova MA, et al. Preventive maintenance and intensive therapy of pneumonias in patients with ischemic insult. Siberian Medical Journal (Irkutsk). 2007;2:41-4 (in Russian)].</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hannawi Y, Hannawi B, Rao CPV. Stroke-associated pneumonia: Major advances and obstacles. Cerebrovasc Dis. 2013;35(5):430-43. DOI:10.1159/000350199</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Singh P, Singh M, Singh NH, et al. A novel haplotype within C-reactive protein gene influences CRP levels and coronary heart disease risk in Northwest Indians. Mol Biol Rep. 2014;41(9):5851-62. DOI:10.1007/s11033-014-3459-0</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Dawood FZ, Judd S, Howard V, et al. High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2016;118(12):1826-30. DOI:10.1016/j.amjcard.2016.08.069</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Schulz S, Ludike H, Lierath M, Schlitt A. C-reactive protein levels and genetic variants of CRP as prognostic markers for combined cardiovascular endpoint (cardiovascular death, death from stroke, myocardial infarction, and stroke/TIA). Cytokine. 2016;88:71-6. DOI:10.1016/j.cyto.2016.08.021</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hutanu A, Iancu M, Balasa R. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. Acta Pharmacol Sin. 2018;39(7):1228-36. DOI:10.1038/aps.2018.26</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mazaheri S, Reisi E, Poorolajal J, Ghiasian M. C-Reactive Protein Levels and Clinical Outcomes in Stroke Patients: A Prospective Cohort Study. Arch Iran Med. 2018;21(1):8-12.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Matsuo R, Ago T, Hata J. Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study. PLoS One. 2016;11(6):e0156790. DOI:10.1371/journal.pone.0156790</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Anrather J, Iadecola C. Inflammation and Stroke: An Overview. Neurotherapeutics. 2016;13(4):661-70. DOI:10.1007/s13311-016-0483-x</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rayasam A, Hsu M, Hernandez G, et al. Contrasting roles of immune cells in tissue injury and repair in stroke: The dark and bright side of immunity in the brain. Neurochem Int. 2017;107:104-16. DOI:10.1016/j.neuint.2017.02.009</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pusch G, Debrabant B, Molnar T, Gergely F. Early Dynamics of P-selectin and Interleukin 6 Predicts Outcomes in Ischemic Stroke. J Stroke Cerebrovasc Dis. 2015;24(8):1938-47. DOI:10.1016/j.jstrokecerebrovasdis.2015.05.005</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fahmi RM, Elsaid AF, Ahmed F. Infarction Size, Interleukin-6, and Their Interaction Are Predictors of Short-Term Stroke Outcome in Young Egyptian Adults. J Stroke Cerebrovasc Dis. 2016;25(10):2475-81. DOI:10.1016/j.jstrokecerebrovasdis.2016.06.021</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Murr С, Widner B, Wirleitner B, Fuchs D. Neopterin as a Marker for Immune System Activation. Curr Drug Metab. 2002;3(2):175-87. DOI:10.2174/1389200024605082</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zeng X, Zhang G, Yang B, et al. Neopterin as a Predictor of Functional Outcome and Mortality in Chinese Patients with Acute Ischemic Stroke. Mol Neurobiol. 2016;53(6):3939-47. DOI:10.1007/s12035-015-9310-3</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Vogelgesang A, Lange C, Blumke L, et al. Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function. J Neuroinflammation. 2017;14(1):140. DOI:10.1186/s12974-017-0914-6</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Shang J, Yamashita T, Fukui Y. Different Associations of Plasma Biomarkers in Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, and Ischemic Stroke. J Clin Neurol. 2018;14(1):29-34. DOI:10.3988/jcn.2018.14.1.29</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Azurmendi L, Lapierre-Fetaud V. Proteomic discovery and verification of serum amyloid A as a predictor marker of patients at risk of post-stroke infection: a pilot study. Clin Proteomics. 2017;14:27. DOI:10.1186/s12014-017-9162-0</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Каминный А.И., Павлунина Т.О., Шувалова Ю.А., Коротаева А.А. Роль секреторной фосфолипазы А2 в развитии атеросклероза. Атеросклероз и дислипидемии. 2012;4(9):63-8 [Kaminnyi AI, Pavlunina TO, Shuvalova JuA, Korotaeva AA. Secretory phospholipase A2 and the development of atherosclerosis. Ateroskleroz i dislipidemii. 2012;4(9):63-8 (in Russian)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Hoda MN, Singh I, Singh AK, Khan M. Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat. J Neuroinflammation. 2009;6:21. DOI:10.1186/1742-2094-6-21</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ji R, Wang D, Shen H, et al. Interrelationship among common medical complications after acute stroke: pneumonia plays an important role. Stroke. 2013;44(12):3436-44. DOI:10.1161/STROKEAHA.113.001931</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Pepe MS. The statistical evaluation of medical tests for classification and prediction. New York, NY: Oxford University Press, 2004.</mixed-citation></ref></ref-list></back></article>
